Does smoking affect psoriasis biologics
#1
The aim of this study was to assess drug survival and the efficacy of biologics for psoriasis in smokers compared with non-smokers.


Quote:
Background:
Smoking is a modifiable risk factor that increases the likelihood of developing psoriasis and the severity of the disease. In recent years, biological therapies have transformed the management of psoriasis. There is conflicting evidence about whether smoking affects the efficacy of biologics. The aim of this study was to assess drug survival and the efficacy of the first biologic for psoriasis in smokers compared with non-smokers.

Methods:
This was a retrospective cohort study using data from the Australasian Psoriasis Registry. Participants with psoriasis who met Pharmaceutical Benefits Scheme eligibility criteria for a biologic (n = 395) were included. Associations between smoking and drug survival or Psoriasis Area and Severity Index (PASI) response were assessed using univariable and multivariable Cox Proportional Hazards regression, controlling for confounders including sex, obesity, psoriatic arthritis, biologic class and baseline PASI.

Results:
The prevalence of current smoking was 24.6% and former smoking was 18.5%. On univariable analysis, smokers were 34% more likely to discontinue treatment compared with non-smokers (p = 0.039), were 27% less likely to attain PASI90 (p = 0.037) and 33% less likely to attain PASI100 (p = 0.038). On multivariable analysis, the association between smoking and reduced drug survival was no longer statistically significant. Multiple factors, including obesity, female sex, psoriatic arthritis and higher PASI scores, were risk factors for drug discontinuation.

Conclusions:
This analysis illustrated that multiple factors are involved in drug survival, and smoking was not an independent risk factor for drug discontinuation. This study provides a rationale for future studies examining the effect of lifestyle modification on the efficacy of biological therapies in psoriasis.

Source: onlinelibrary.wiley.com

*Funding: Skin Cancer Foundation
Reply
#2
I don’t think we’re supposed to be smoking the biologics, they’re for injecting.. Rolleyes
Reply
#3
(Tue-04-03-2025, 15:48 PM)Turnedlight Wrote: I don’t think we’re supposed to be smoking the biologics, they’re for injecting.. Rolleyes

85 Clap
Reply
#4
(Tue-04-03-2025, 15:53 PM)Kat Wrote:
(Tue-04-03-2025, 15:48 PM)Turnedlight Wrote: I don’t think we’re supposed to be smoking the biologics, they’re for injecting.. Rolleyes

85  Clap

Snigger

I don’t see how a high-PASI score is a risk factor.

I can get that a combination of risk factors will/can give a high PASI-score.
Reply


Possibly Related Threads…
Thread Author Replies Views Last Post
  Covid outcomes in psoriasis patients using biologics Fred 0 1,546 Wed-10-06-2026, 11:06 AM
Last Post: Fred
  Treating stubborn psoriasis patches with biologics Fred 3 2,090 Sat-25-04-2026, 16:55 PM
Last Post: glenda grant
  IL-23 and IL-17 inhibitors versus other biologics for psoriasis Fred 0 2,335 Fri-30-05-2025, 15:40 PM
Last Post: Fred
  Switching biologics for psoriasis over time. Fred 6 11,129 Sun-24-07-2022, 11:29 AM
Last Post: Fred
  Effectiveness of (IL)-17A to other biologics in patients with psoriasis Fred 3 6,810 Fri-01-07-2022, 11:57 AM
Last Post: Fred



Users browsing this thread: 1 Guest(s)